We are live on
!
Find out more
BCM
BML Capital Management Portfolio holdings
AUM
$156M
1-Year Est. Return
129.82%
This Fund
S&P 500
This Quarter
Est. Return
-2.01%
1 Year Est. Return
+129.82%
3 Year Est. Return
+394.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$109M
AUM Growth
-$2.27M
(-2%)
Cap. Flow
+$5.33M
Cap. Flow
% of AUM
4.9%
Top 10 Holdings %
Top 10 Hldgs %
89.62%
Holding
33
New
2
Increased
7
Reduced
6
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-3 Month Treasury Bond ETF
SGOV
|
+$9.04M |
| 2 |
Atea Pharmaceuticals
AVIR
|
+$8.72M |
| 3 |
TECX
Tectonic Therapeutic
TECX
|
+$5.52M |
| 4 |
CLYM
Climb Bio
CLYM
|
+$968K |
| 5 |
VistaGen Therapeutics
VTGN
|
+$444K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRDS
Pardes Biosciences, Inc. Common Stock
PRDS
|
+$6.86M |
| 2 |
Abercrombie & Fitch
ANF
|
+$4.43M |
| 3 |
ADVM
Adverum Biotechnologies
ADVM
|
+$2.23M |
| 4 |
Quince Therapeutics
QNCX
|
+$2.12M |
| 5 |
Tilly's
TLYS
|
+$1.34M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.73% |
| 2 | Technology | 2.04% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 0-3 Month Treasury Bond ETF
SGOV
$97.5B
| $27.2M | 24.96% |
270,000
+90,000
| +50% | +$9.04M |
|
2
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$46.8B
| $18.4M | 16.86% |
200,000
| – | – |
|
|
3
Atea Pharmaceuticals
AVIR
$390M
| $14.4M | 13.22% |
4,800,000
+2,563,761
| +115% | +$8.72M |
|
|
CYT
4
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| $9.23M | 8.48% |
3,250,008
+8
| +0% | +$22 |
|
|
TECX
5
Tectonic Therapeutic
TECX
$615M
| $6.16M | 5.66% |
333,469
+312,113
| +1,461% | +$5.52M |
|
|
ADVM
6
DELISTED
Adverum Biotechnologies
ADVM
| $5.87M | 5.39% |
391,500
-124,218
| -24% | -$2.23M |
|
|
TRML
7
DELISTED
Tourmaline Bio
TRML
| $5.62M | 5.16% |
200,000
| – | – |
|
|
CLYM
8
Climb Bio
CLYM
$727M
| $5.1M | 4.68% |
1,938,263
+355,093
| +22% | +$968K |
|
|
LONA
9
LeonaBio Inc
LONA
$67.8M
| $3.44M | 3.16% |
170,436
-16,055
| -9% | -$411K |
|
10
Astrotech Corp
ASTC
$15.5M
| $2.23M | 2.04% |
220,410
| – | – |
|
11
Oramed Pharmaceuticals
ORMP
$165M
| $2.04M | 1.87% |
781,292
-68,708
| -8% | -$216K |
|
|
ORKA
12
Oruka Therapeutics
ORKA
$5.59B
| $1.42M | 1.3% |
58,911
| – | – |
|
13
Passage Bio
PASG
$15.5M
| $1.35M | 1.24% |
102,938
| – | – |
|
14
Forte Biosciences
FBRX
$1B
| $1.17M | 1.07% |
70,468
+1,065
| +2% | +$23.6K |
|
15
Milestone Pharmaceuticals
MIST
$148M
| $845K | 0.78% |
272,500
| – | – |
|
16
Enliven Therapeutics
ELVN
$3.8B
| $683K | 0.63% |
50,000
-24,232
| -33% | -$408K |
|
17
Retractable Technologies
RVP
$20.5M
| $595K | 0.55% |
499,959
-168,616
| -25% | -$198K |
|
18
Verrica Pharmaceuticals
VRCA
$96M
| $583K | 0.54% |
15,000
| – | – |
|
|
19
VistaGen Therapeutics
VTGN
$9.4M
| $524K | 0.48% |
+100,000
| New | +$444K |
|
20
Lisata Therapeutics
LSTA
$32.8M
| $522K | 0.48% |
243,839
| – | – |
|
21
PUT
Invesco QQQ Trust
QQQ
$466B
| $444K | 0.41% |
+108
| New | +$40K |
|
22
NextCure
NXTC
$24.4M
| $395K | 0.36% |
25,539
| – | – |
|
23
Neurogene
NGNE
$744M
| $390K | 0.36% |
24,666
+23,479
| +1,978% | +$347K |
|
24
CalciMedica
CALC
$11.6M
| $236K | 0.22% |
88,781
| – | – |
|
|
RAIN
25
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $62.8K | 0.06% |
72,926
| – | – |
|
Similar funds
AIS
BWM
TI
CFG
IWA
PFO
HCWM
BCM
BML Capital Management's Q3 2023 Portfolio in Review
As of Q3 2023, BML Capital Management held 33 positions worth $109M, down 2% from $111M the previous quarter. Its ten largest holdings account for 90% of the portfolio.
BML Capital Management deployed $5.33M of net new capital in Q3 2023, opening 2 new positions and adding to 7 existing holdings. Its largest new stake was VistaGen Therapeutics: 100,000 shares worth $524K.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 59% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Adverum Biotechnologies, an estimated $2.23M trimmed.
- BML Capital Management's largest Q3 2023 buy was VistaGen Therapeutics: 100,000 shares worth $524K.
- BML Capital Management added most to iShares 0-3 Month Treasury Bond ETF in Q3 2023, an estimated $9.04M increase.
- BML Capital Management's biggest Q3 2023 reduction was Adverum Biotechnologies, cutting an estimated $2.23M.
- BML Capital Management fully exited Pardes Biosciences, Inc. Common Stock in Q3 2023, selling an estimated $6.86M.
- BML Capital Management's ten largest holdings make up 90% of its $109M portfolio in Q3 2023.
- BML Capital Management opened 2 new positions and closed 7 in Q3 2023.
- BML Capital Management's portfolio value fell 2% quarter-over-quarter to $109M.
Based on BML Capital Management's 13F filing for Q3 2023, filed 23 Oct 2023.